secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moderna, Inc. (MRNA)
CIK:        0001682852
Form:       8-K
Filed at:   2026-07-31T11:03:47+00:00
Accession:  0001682852-26-000147
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moderna Q2 net loss $(0.8)B, EPS $(1.97); norovirus vaccine misses interim endpoint
--------------------------------------------------------------------------------

- Q2 revenue $145M (flat YoY); GAAP net loss $(0.8)B, EPS $(1.97) vs $(2.13) in Q2 2025.
- 2026 guidance: targeting up to 10% revenue growth; year-end cash improved to $4.7-5.2B; R&D expense lowered to ~$2.9B.
- Norovirus vaccine mRNA-1403 failed early success criteria at Phase 3 interim; enrolling additional cohort.
- mFLUSIVA (flu vaccine) PDUFA date Aug 5, 2026; potential fifth approved product.
- Appointed Ester Banque as CCO and Michael McDonnell to Board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/0001682852-26-000147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682852/000168285226000147/mrna-20260731.htm
  HTML page:      https://secwatch.observer/filing/0001682852-26-000147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer